BACKGROUND: In non-small cell lung cancer (NSCLC), platelet-derived growth 
factor receptor (PDGFR) mediates angiogenesis, tissue invasion, and tumor 
interstitial pressure. Olaratumab (IMC-3G3) is a fully human anti-PDGFRα 
monoclonal antibody. This Phase II study assessed safety and efficacy of 
olaratumab+paclitaxel/carboplatin (P/C) versus P/C alone for previously 
untreated advanced NSCLC.
MATERIALS AND METHODS: Patients received up to six 21-day cycles of P 200mg/m2 
and C AUC 6 (day 1)±olaratumab 15mg/kg (days 1 and 8). Primary endpoint was PFS. 
Olaratumab was continued in the olaratumab+P/C arm until disease progression.
RESULTS: 131 patients were: 67 with olaratumab+P/C and 64 with P/C; 74% had 
nonsquamous NSCLC. Median PFS was similar between olaratumab+P/C and P/C (4.4 
months each) (HR 1.29; 95% CI [0.86-1.93]; p=0.21). Median OS was similar 
between olaratumab+P/C (11.8 months) and P/C (11.5 months) (HR 1.04; 95% CI 
[0.68-1.57]; p=0.87). Both arms had similar toxicity profiles. All evaluable 
cases were PDGFR-negative by immunohistochemistry. Tumor stroma PDGFR expression 
was evaluable in 23/131 patients, of which 78% were positive.
CONCLUSIONS: The addition of olaratumab to P/C did not result in significant 
prolongation of PFS or OS in advanced NSCLC. Olaratumab studies in other patient 
populations, including soft tissue sarcoma (NCT02783599), pancreatic cancer 
(NCT03086369), and pediatric malignancies (NCT02677116) are underway.